The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 29, 2021

Filed:

Apr. 19, 2017
Applicant:

Yuhan Corporation, Seoul, KR;

Inventors:

Su Youn Nam, Seoul, KR;

Jong Gyun Kim, Gyeonggi-do, KR;

Byung Hyun Choi, Gyeonggi-do, KR;

June Hyung Lee, Seoul, KR;

Ju Young Park, Gyeonggi-do, KR;

Jun Kyung Lee, Gyeonggi-do, KR;

Na Rae Lee, Seoul, KR;

Ki Hong Kim, Gyeonggi-do, KR;

Seul Gi Kim, Gyeonggi-do, KR;

Se Woong Oh, Gyeonggi-do, KR;

Seung Yub Shin, Gyeonggi-do, KR;

Ho Woong Kang, Gyeonggi-do, KR;

Su Jin Ahn, Gyeonggi-do, KR;

Soo Yong Chung, Gyeonggi-do, KR;

Assignee:

YUHAN CORPORATION, Seoul, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/52 (2006.01); C07K 19/00 (2006.01); C12N 15/09 (2006.01); C12N 15/11 (2006.01); C12N 15/63 (2006.01); A61K 38/19 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01); A61K 47/50 (2017.01);
U.S. Cl.
CPC ...
C07K 14/523 (2013.01); A61K 38/195 (2013.01); A61K 47/68 (2017.08); A61P 35/00 (2018.01); C07K 19/00 (2013.01); C12N 15/09 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); A61K 38/00 (2013.01); A61K 47/50 (2017.08); C07K 2319/30 (2013.01);
Abstract

Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3α or CCL3β is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3α or CCL3β in the CCL3 variant.


Find Patent Forward Citations

Loading…